🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 16 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/12/1998 | 13,88 | 13,91 | 13,69 | 13,78 | -0,90% | 1,58% | 538.600 |
| 04/12/1998 | 13,78 | 14,19 | 13,75 | 13,91 | +2,30% | 3,17% | 751.600 |
| 03/12/1998 | 12,94 | 13,59 | 12,75 | 13,59 | +6,62% | 6,52% | 932.800 |
| 02/12/1998 | 12,31 | 13,25 | 12,06 | 12,75 | +5,70% | 9,64% | 428.600 |
| 01/12/1998 | 11,81 | 12,31 | 11,78 | 12,06 | +1,85% | 4,50% | 208.400 |
| 30/11/1998 | 11,75 | 12,00 | 11,75 | 11,84 | -0,78% | 2,13% | 249.000 |
| 27/11/1998 | 11,50 | 11,94 | 11,50 | 11,94 | +3,80% | 3,80% | 128.000 |
| 25/11/1998 | 11,75 | 11,94 | 11,50 | 11,50 | -3,16% | 3,72% | 147.400 |
| 24/11/1998 | 12,06 | 12,13 | 11,78 | 11,88 | -2,31% | 2,85% | 290.200 |
| 23/11/1998 | 12,44 | 12,50 | 12,00 | 12,16 | -1,27% | 4,02% | 233.200 |
| 20/11/1998 | 12,38 | 12,50 | 12,25 | 12,31 | -1,50% | 2,02% | 194.400 |
| 19/11/1998 | 12,38 | 12,50 | 12,28 | 12,50 | +1,78% | 1,77% | 254.000 |
| 18/11/1998 | 12,31 | 12,50 | 12,19 | 12,28 | -0,25% | 2,54% | 86.000 |
| 17/11/1998 | 12,31 | 12,50 | 12,31 | 12,31 | -1,25% | 1,52% | 51.600 |
| 16/11/1998 | 12,75 | 13,00 | 12,19 | 12,47 | -1,72% | 6,37% | 111.400 |
| 13/11/1998 | 12,94 | 12,94 | 12,69 | 12,69 | -0,98% | 1,93% | 85.400 |
| 12/11/1998 | 12,63 | 12,94 | 12,63 | 12,81 | +0,99% | 2,48% | 78.800 |
| 11/11/1998 | 12,75 | 13,00 | 12,50 | 12,69 | -0,98% | 3,92% | 177.200 |
| 10/11/1998 | 12,81 | 12,88 | 12,38 | 12,81 | +1,49% | 3,90% | 123.000 |
| 09/11/1998 | 13,00 | 13,38 | 12,44 | 12,63 | -5,16% | 7,21% | 300.800 |
| 06/11/1998 | 12,63 | 13,38 | 12,63 | 13,31 | +5,45% | 5,94% | 89.800 |
| 05/11/1998 | 12,88 | 12,88 | 12,06 | 12,63 | -3,58% | 6,31% | 233.400 |
| 04/11/1998 | 13,56 | 13,75 | 12,94 | 13,09 | -3,90% | 5,99% | 394.600 |
| 03/11/1998 | 13,44 | 13,63 | 13,13 | 13,63 | +0,93% | 3,72% | 196.400 |
| 02/11/1998 | 13,16 | 13,63 | 13,16 | 13,50 | +2,37% | 3,56% | 401.000 |
| 30/10/1998 | 13,31 | 13,50 | 13,13 | 13,19 | -0,94% | 2,82% | 391.200 |
| 29/10/1998 | 13,25 | 13,38 | 13,00 | 13,31 | +1,43% | 2,83% | 496.400 |
| 28/10/1998 | 12,81 | 13,19 | 12,75 | 13,13 | +1,94% | 3,41% | 214.400 |
| 27/10/1998 | 13,16 | 13,38 | 12,81 | 12,88 | -2,37% | 4,28% | 1.072.000 |
| 26/10/1998 | 12,56 | 13,19 | 12,13 | 13,19 | +5,50% | 8,46% | 454.800 |